A proof-of-concept clinical trial of WP-1220 for the treatment of cutaneous T-cell lymphoma (CTCL)

Trial Profile

A proof-of-concept clinical trial of WP-1220 for the treatment of cutaneous T-cell lymphoma (CTCL)

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs MOL 4239 (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 14 Sep 2017 New trial record
    • 13 Sep 2017 According to a Moleculin Biotech media release, the company is planning to apply to the Polish regulatory authorities for a clinical trial authorization.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top